Challenge TB | Lead Partner: KNCV | Country Director: Dr. Nguyen Thien Huong
Vietnam is one of thirty countries that not only has a high-burden of TB but also a high burden of multidrug-resistant TB, according to the WHO Global Tuberculosis Report 2018.
Over the past five years (2012-2017) the TB mortality rate in Vietnam has steadily declined by 8% per year and well exceeds the global average. Vietnam has also achieved a high treatment success right (above 70%), again well above the global average of 55%. Despite these gains, 12,000 people per population of 100,000 died of TB in 2017.
The overall strategy of Challenge TB in Vietnam is to develop, pilot and evaluate TB care and prevention innovations that are planned under the National Strategic Plan 2015-2020, in close collaboration with the NTP, VAAC, the USAID Mission and partners. After evaluation and ensuring adjustments, the innovations will be mainstreamed by the NTP with domestic and other donor (mainly GF) resources. This approach was shown to be effective during TB CAP and TB CARE I implementation. In this way Challenge TB investments will leverage other resources, while spearheading program innovation. Challenge TB will also ensure effective use of Global Fund investments, by providing technical assistance to the rollout of the innovations. Evidence will be collected to document the operational processes and their impact.
In 2017, the CTB Vietnam saw the introduction and scale-up of GeneXpert machines make a significant contribution to the diagnosis of MDR-TB patients in the country. An additional 65 GeneXpert systems have been introduced with Vietnam being the first country to offer multi-disease testing devices through GeneXpert platforms, for TB and HIV testing.
CTB has provided provincial and district level capacity building through the implementation of comprehensive, patient-centered TB/HIV services in Nghe An and Dien Bien provinces.
Progress also is being achieved in scaling-up Programmatic Management of Drug-resistant TB (PMDT). Vietnam pioneered the Patient Triage approach for RR-TB patients using SL-LPA as the initial diagnostic test for the detection of fluoroquinolone- and second-line injectable resistance. As of September 30, 2017 the first approved of 99 pre-XDR and XD-TB patients in three pilot provinces have been triaged and enrolled on bedaquiline-containing treatment regimens. The first approved 101 MDR-TB patients enrolled on the shorter 9 month regimen (using levofloxacin) finished their treatment course in 2017.
CTB Vietnam has also supported the NTP in the development and implementation of the second National TB Prevalence Survey. This survey will provide a precise overview of the current TB burden plus essential information for developing the Vietnam TB elimination strategy as well as estimating funding needs for interventions.
KNCV Tuberculosis Foundation in Vietnam
130 Mai Anh Tuan Str., DongDa Dist.